Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New role for tamoxifen as fertility drug for breast cancer patients?

08.01.2003


US fertility experts have discovered a potential new role for the wonder drug tamoxifen – helping breast cancer patients to have babies by IVF.



In a study published in Europe’s leading reproductive medicine journal Human Reproduction[1], researchers from New York’s Cornell University report the first IVF pregnancy to result from the use of tamoxifen as an ovarian stimulant.

In a study of 12 breast cancer survivors they found that stimulating the ovaries with a short, carefully timed course of tamoxifen boosted the number of eggs they could retrieve. Every patient had one or more embryos either for freezing for later attempts at pregnancy, or for immediate transfer. One patient who had two fresh embryos transferred has already given birth to twins. Another patient conceived on her second attempt although she miscarried. None of the patients with frozen embryos has yet attempted pregnancy.


Lead researcher Professor Kutluk Oktay said that the experiment arose from a desire to find a safe way of preserving fertility among the 15% of breast cancer patients – around 27,000 annually in the USA – who were still of reproductive age when they were diagnosed.

Chemotherapy causes ovarian failure in many patients – nearly as many as four out of five women in the case of those given cyclophosphamide. Even those who remain fertile or don’t have chemotherapy face the problem of needing a recurrence-free period of perhaps two to five years before trying to conceive, bringing them up against the barrier of infertility due to ageing and diminishing ovarian reserves.

"These women can try natural cycle IVF without ovarian stimulation, but typically, no more than a single embryo can be achieved for immediate use or freezing. So, we need to find a safe way of increasing the number of embryos to give these women a better chance of having a baby," said Professor Oktay, assistant professor of Reproductive Medicine and Obstetrics and Gynaecology at the Center for Reproductive Medicine and Infertility, Weill Medical College of Cornell University.

Tamoxifen was developed in the UK in 1966 as a contraceptive, but found to stimulate ovarian follicle growth and became used in Europe as an ovarian stimulant. (A related compound, Clomiphene, is usually used in the USA). It wasn’t until 1976 that tamoxifen’s suppressive, anti-estrogenic effect on breast cancer was discovered. Since then it has become the world’s most successful anti-cancer drug, saving the lives of thousands of breast cancer patients every year worldwide.

"Sometimes the best ideas are the obvious ones and tamoxifen seemed the obvious choice of drug to test, although, to my knowledge, no one has tried it before in breast cancer patients," said Professor Oktay. "We hypothesised that tamoxifen stimulation would result in higher numbers of embryos compared with natural cycle IVF, while theoretically shielding breast cancer cells against oestrogen."

A retrospective group of five breast cancer patients who had undergone nine cycles of natural cycle IVF was used as a control for the 12 study patients. The 12 patients were given 40-60 mg tamoxifen for around seven days on days 2-3 of their menstrual cycle (a total of 15 treated cycles). The tamoxifen patients produced a greater number of mature eggs than the controls (1.6 versus 0.7) and embryos (1.6 versus 0.6). All tamoxifen patients generated embryos compared with three out of five controls. After a mean follow up of around 15 months none of the study patients has had a recurrence of cancer.

"This is a novel use of tamoxifen to attempt to preserve fertility and treat chemotherapy-related infertility via IVF embryo cryopreservation and embryo transfer after breast cancer," said Professor Oktay. "We exploited tamoxifen’s dual action as an ovarian stimulating drug and an anti-cancer agent."

Because most patients in the tamoxifen group froze their embryos while most in the control group had fresh embryo transfer it has not been possible yet to compare pregnancy rates between the two protocols or to provide long-term data on the effects of tamoxifen on pregnancy. However, long-term experience of the drug in ovulation induction did not suggest an embryo-damaging effect. In any case its use was discontinued prior to ovulation and egg retrieval and IVF embryos were never exposed to it as fertilisation took place in vitro.

Professor Oktay said the study had limitations with its short follow-up and its retrospective, small control group, but a larger study was planned with modifications to the protocol to include low amounts of follicle stimulating hormone (FSH) in addition to tamoxifen.

"I am optimistic," he said. "Many of my patients tell me that just doing something to address the issue of loss of reproductive function makes it easier for them to deal with breast cancer. It connects them to their future and underlines that because they have breast cancer it does not mean they have a terminal illness.

"It would be especially fitting if a drug that has saved so many women’s lives should also turn out to be a means of preserving their fertility," he added.

He urged all breast cancer physicians to be aware of the effect of chemotherapy on women of reproductive age and to refer them to an appropriate assisted reproduction centre as soon as a diagnosis was made so that options for preserving fertility could be discussed.


[1] Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Human Reproduction. Vol. 18. No 1. pp 90-95.

Notes:
1 PDF version of this press release and full embargoed text of the paper with complete results can be found from 09.00hrs GMT Monday 6 January on: http://www3.oup.co.uk/eshre/press-release/jan03.pdf or is available immediately from Margaret Willson.
2 Human Reproduction is a monthly journal of the European Society of Human Reproduction and Embryology (ESHRE). Please acknowledge Human Reproduction as a source.
3 ESHRE’s website is: http://www.eshre.com
4 Abstracts of other papers in ESHRE’s three journals: Human Reproduction, Molecular Human Reproduction & Human Reproduction Update can be accessed post embargo from: http://www3.oup.co.uk/eshre/ Full text of papers available on request from Margaret Willson.

Magaret Willson | EurekAlert!
Further information:
http://www.eshre.com/
http://www3.oup.co.uk/eshre/press-release/jan03.pdf
http://www3.oup.co.uk/eshre/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Stronger turbine blades with molybdenum silicides

26.09.2016 | Materials Sciences

Scientists Find Twisting 3-D Raceway for Electrons in Nanoscale Crystal Slices

26.09.2016 | Materials Sciences

Lowering the Heat Makes New Materials Possible While Saving Energy

26.09.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>